A second novel drug target has been generated in AstraZeneca and BenevolentAI’s artificial intelligence-assisted drug discovery partnership, this time in idiopathic pulmonary fibrosis (IPF).
This represents another significant milestone in the collaboration, following the addition of a novel chronic kidney disease (CKD) target to AstraZeneca’s roster in January 2021, and
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?